Optimizing glycemic control: clinical utility of exenatide prolonged release injection

References

• Weir GC, Leahy JL. Pathogenesis of non-insulin-dependent (type II) diabetes mellitus. In: Kahn CR, Weir GE, editors. Joslin s Diabetes Mellitus. 13th ed. Philadelphia, PA: Lea and Febiger; 1994: 240–264.
   Google Scholar
• Bogardus C. Metabolic abnormalities in the development of non-insulindependent diabetes mellitus. In: LeRoith D, Taylor SI, Olefski JM, editors. Diabetes mellitus. Philadelphia, PA: Lippincot-Raven Publishers; 1996:459.
   Google Scholar
• DeFronzo RA. Lilly Lecture 1987. The triumvirate: beta-cell, muscle, liver. A collision responsible for NIDDM. Diabetes. 1988;37(6):667–687.
   Google Scholar
• Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787–794.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. NEngl J Med. 2008;359(15):1577–1589.
   PubMed Web of Science ®Google Scholar
• de Boer IH, Rue TC, Cleary PA, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med. 2011;171(5):412–420.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care. 2012;35 Suppl 1:S11-S63.
   Google Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574–583.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541–549.
   PubMed Web of Science ®Google Scholar
• Groop L. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737–747.
   PubMed Web of Science ®Google Scholar
• Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol. 2003;2(6):401–414.
   PubMedGoogle Scholar
• Derosa G, Maffioli P. Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clin Ther. 2012;34(6):1221–1236.
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65(3):385–411
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118.
   Web of Science ®Google Scholar
• Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther. 2010;12(6):491–501.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007;30(8):2148–2153.
   PubMed Web of Science ®Google Scholar
• Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes ObesMetab. 2009;11(12):1091–1099.
   PubMed Web of Science ®Google Scholar
• Meymeh RH, Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ. 2007;177(7):723–724.
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439.
   PubMed Web of Science ®Google Scholar
• Tourrel C, Zhao Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001;50(7):1562–1570.
   PubMed Web of Science ®Google Scholar
• Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology. 2003;144(4):1444–1455.
   PubMed Web of Science ®Google Scholar
• Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000;141(12):4600–4605.
   PubMed Web of Science ®Google Scholar
• Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, p-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. June 8, 2012. [Epub ahead of print.]
   Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism. 2010;59(6):887–895.
   PubMed Web of Science ®Google Scholar
• Derosa G, Ragonesi PD, Carbone A, et al. Vildagliptin added to metformin on p-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther. 2012;14(6):475–484.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res. 2010;42(9):663–669.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2011;4:263–271.
   PubMedGoogle Scholar
• Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther. 2012;14(4):350–364.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr Clin Pharmacol. 2012;7(3):214–228.
   Google Scholar
• Derosa G, Franzetti IG, Querci F, et al. Exenatide plus metformin compared with metformin alone on p-cell function in patients with Type 2 diabetes. DiabetMed. April 30, 2012. doi: 10.1111/j.1464–5491.2012.03699.x. [Epub ahead of print.]
   Google Scholar
• Derosa G, Putignano P, Bossi AC, et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol. 2011;666(1–3):251–256.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther. 2010;12(3):233–240.
   PubMed Web of Science ®Google Scholar
• Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286–1291.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402–7405.
   PubMed Web of Science ®Google Scholar
• Young AA. Chapter 14. Glucagon-like peptide-1, exendin and insulin sensitivity. In: Hansen B, Shafrir E, editors. Insulin Resistance and Insulin Resistance Syndrome. New York: Taylor and Francis; 2002: 235–262.
   Google Scholar
• Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664–1669.
   PubMed Web of Science ®Google Scholar
• Knudsen LB. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem. 2004;47(17):4128–4134.
   Web of Science ®Google Scholar
• Parkes D, Jodka C, Smith P, et al. Pharmacokinetic actions of exenatide-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res. 2001;53:260–267.
   Web of Science ®Google Scholar
• Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. CurrDrugMetab. 2006;7(4):367–374.
   Google Scholar
• Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia. 2006;49(4):706–712.
   Web of Science ®Google Scholar
• Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64(3):317–327.
   PubMed Web of Science ®Google Scholar
• Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487–1493.
   PubMed Web of Science ®Google Scholar
• Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2009;18(3):359–367.
   PubMed Web of Science ®Google Scholar
• Tracy MA, Ward KL, Firouzabadian L, et al. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 1999;20(11):1057–1062.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Bydureon. EPAR summary for the public [document on the Internet]. London, UK: European Medicines Agency [updated May 2011]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002020/WC500108240.pdf. Accessed May 13, 2011.
   Google Scholar
• Department of Health and Human Services. Summary Review [document on the Internet]. Silver Spring, MD: Center for Drug Evaluation and Research [updated January 27, 2012]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000SumR. pdf. Accessed Aug 5, 2012.
   Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al; for DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250.
   PubMed Web of Science ®Google Scholar
• Novo Nordisk Inc. NDA 22–341 VICTOZA&® (Liraglutide [rDNA origin] Injection). Risk Evaluation and Mitigation Strategy (REMS) [document on the Internet]. Silver Spring, MD: Food and Drug Association [updated May 2011]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM202063.pdf. Accessed May 13, 2011.
   Google Scholar
• Pharmalot. Lily’s once-weekly byetta may have cancer risk [homepage on the Internet]. Hamilton, NJ: UBM Canon. Available from: http://www.pharmalot.com/2010/04/lillys-once-weekly-byetta-may-have-cancer-risk/. Accessed April 12, 2010.
   Google Scholar
• Nielsen LL, Okerson T, Holcombe J, Hoogwerf B. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diabetes Sci Technol. 2008;2(2):255–260.
   Google Scholar
• Buse JB, Drucker DJ, Taylor KL, et al; for DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33(6):1255–1261.
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–1310.
   PubMed Web of Science ®Google Scholar
• Ridge T, Moretto T, Macconell L, et al. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Diabetes Obes Metab. June 26, 2012. doi: 10.1111/j.1463-1326.2012.01639.x. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, MacConell L, et al; for DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–439.
   PubMed Web of Science ®Google Scholar
• Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011;28(6):705–714.
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234–2243.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Cuddihy RM, Hanefeld M, et al; for DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252–258.
   PubMed Web of Science ®Google Scholar
• Lilly. DURATION-6 Top-Line Study Results Announced [homepage on the Internet]. Indianapolis, IN: Eli Lilly and Company. Available from: http://investor.lilly.com/releasedetail2.cfm?ReleaseID=554248. Accessed March 25, 2011.
   Google Scholar
• Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis. J Med Econ. April 26, 2012. [Epub ahead of print.]
   Google Scholar
• Gaebler JA, Soto-Campos G, Alperin P, et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag. 2012;8:255–264.
   PubMedGoogle Scholar
• Guillermin AL, Lloyd A, Best JH, Deyoung MB, SamyshkinY, Gaebler JA. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. J Med Econ. 2012;15(4):654–663.
   PubMedGoogle Scholar
• Amylin Pharmaceuticals, LLC. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitu. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated August 26, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01144338. NLM identifier: NCT01144338. Accessed September 3, 2012.
   Google Scholar